Recensa is developing small molecules that activate the transcription factor Nrf2, a key modulator of antioxidant response. These molecules will be embedded in topical vehicles-such as creams or lotions-and will be tested in animal models of psoriasis so we can gain FDA approval for human clinical trials. Future products may target other diseases